



Biotech Daily

Monday October 2, 2017

Daily news on ASX-listed biotechnology companies

- * **SEPTEMBER BDI-40 UP 4%, ASX200 DOWN 0.6%, BIG CAPS UP 3.5%**
- LIVING CELL UP 45%, POLYNOVO 36%; ACRUX DOWN 44%
- * **TODAY: ASX, BIOTECH UP: LIVING CELL UP 14%**
- COMPUMEDICS DOWN 10%
- * **FDA LIFTS ANTISENSE PHASE IIb ATL1102 MS TRIAL HOLD**
- * **G MEDICAL APPOINTS MEDTL GREECE, CYPRUS DISTRIBUTOR**
- * **ITL REQUESTS 'TRANSACTION UPDATE' TRADING HALT**
- * **ASX SUSPENDS ANTEO ON ACCOUNTS**

MARKET REPORT

The Australian stock market climbed 0.84 percent on Monday October 2, 2017 with the ASX200 up 47.7 points to 5,729.3 points.

Seventeen of the Biotech Daily Top 40 stocks were up, 11 fell, five traded unchanged and seven were untraded. All three Big Caps were up.

Living Cell was the best, up 2.5 cents or 13.9 percent to 20.5 cents with 5.5 million shares traded.

Cyclopharm climbed six percent; Osprey and Starpharma improved more than four percent; Acrux was up 3.45 percent; Airxpanders, Medical Developments, Nanosonics and Sirtex rose more than two percent; Actinogen, LBT, Neuren, Orthocell, Pro Medicus, Viralytics and Volpara were up more than one percent; with Cochlear, CSL, Mesoblast and Resmed up by less than one percent.

Compumedics led the falls, down 3.5 cents or 9.6 percent to 33 cents with 179,783 shares traded, followed by Prima down eight percent to 2.3 cents with 8.7 million shares traded.

Bionomics and Pharmaxis fell more than three percent; Admedus, Opthea, Reva and Universal Biosensors lost more than one percent; with Clinuvel, Ellex and Impedimed down by less than one percent.

[BIOTECH DAILY TOP 40 INDEX \(BDI-40\)](#)

Spring appears to have sprung for the biotechnology sector – up 4.2 percent in September compared to the ASX200 slipping 0.6 percent – but deceptively from a low base.

The collective market capitalization of the Biotech Daily Top 40 Index (which does not include the three Big Caps of Cochlear, CSL and Resmed) was down \$1,524 million or 18.0 percent for the 12 months to September 30.

Sirtex has lost \$1,081 million (58.4%) to \$771 million over the 12 month period, while Impedimed was down \$302 million (50.2%) to \$299 million, Airxpanders shed \$100 million (30.95%) to \$223 million and Nanosonics retreated \$225 million (22.4%) to \$781 million.

Nanosonics is currently the biggest biotech by market capitalization (after the three Big Caps), followed by Sirtex, Mesoblast (\$645 million) and Pro Medicus (\$610 million).

And the three Big Caps of Cochlear, CSL and Resmed climbed a collective 3.5 percent in September and a significant 20.9 percent for the 12 months to September 30, beating the Nasdaq Biotechnology Index which was up 0.1 percent for the month and 15.4 percent for the year.

For the month of September, CSL climbed 4.3 percent to \$60,628 million, Cochlear rose 1.96 percent to a record high of \$9,161 million and Resmed was up 1.5 percent to \$13,848 million.

Twenty-four of the BDI-40 companies were up, 15 fell and one was unchanged.

Ten were up by more than 10 percent and just three fell by more than 10 percent.

Pro Medicus' \$93 million improvement compensated for the Sirtex \$94 million fall, while Starpharma climbed \$87 million and Nanosonics was up \$84 million, with Living Cell adding \$32 million to the Index and Mesoblast recovering \$20 million.

By percentage, Living Cell was the best, up 45.1 percent to \$103 million, followed by Polynovo (36.1%), Impedimed (27.2%), Neuren (26.4%), Starpharma (22.7%), Oncosil (20.0%), Pro Medicus (18.0%), Ellex (17.9%), Airxpanders (17.4%) and Benitec (16.0%).


Acrux led the falls, shedding 44.2 percent to \$24 million (from an all-time high of \$723 million at May 31, 2012), followed by Viralytics (14.8%) and Sirtex (10.9%).

Outside the BDI-40, Cynata, Optiscan, Phylogica, Probiotec and Volpara have been impressive, with Patrys jumping 433.3 percent to a market capitalization of \$16 million.


Volpara has been promoted into the BDI-40 and Atcor returns to the Third 20.

In the US, Aviragen (Biota) clung to life, up 9.7 percent to \$34 million, Protagonist was up 9.8 percent to a record \$381 million and Redhill was up 28.1 percent to \$237 million.


BDI-40 v ASX200 Jun 30, 2006 to Sep 30, 2017- Adjusted



Big Caps \$m (Cochlear, CSL, Resmed) Sep 30, 2016 – Sep 30, 2017



BDI-40 (\$m) v S&P ASX 200 – Sep 30, 2016 – Sep 30, 2017



ANTISENSE THERAPEUTICS

Antisense says the US Food and Drug Administration has lifted the clinical hold on its phase IIb trial of ATL1102 for multiple sclerosis (BD: Apr 24, Jul 27, 2017).

Antisense said the FDA had approved the trial at a 25mg/week dose for six months.

In 2008, Antisense and its then partner Teva reported safety and efficacy of ATL1102 in a phase IIa trial for multiple sclerosis at a dose of 400mg per week, with the only concern a reduction in blood platelets, or thrombocytopenia, which was reversed after treatment interruption (BD: Jun 30, 2008).

Antisense managing-director Mark Diamond told Biotech Daily the company previously said it expected future trials of ATL1102 be at a dose of 200mg or lower per week.

The company said it would "seek clarification from the FDA" for criteria under which multiple sclerosis patients could receive higher doses in subsequent trials, with the provision of an adequate safety monitoring plan to allow for higher dosing, which was the reason for the dosing restriction under the current investigational new drug application.

Antisense said that in parallel with the FDA process for the multiple sclerosis trial, it had Melbourne's Royal Children's Hospital ethics approval for a trial of ATL1102 for Duchenne muscular dystrophy, subject to FDA clearance of the ATL1102 for multiple sclerosis investigational new drug (IND) application (BD: Sep 12, 2017).

The company said it would return to the ethics committee to confirm the approval status of the Duchenne muscular dystrophy trial "in light of the recent FDA response".

Antisense was untraded at 3.7 cents.

G (GEVA) MEDICAL INNOVATIONS

G Medical says it has appointed the Nikosia, Cyprus-based Medtl Medical Technologies as its Prizma smartphone case distributor for Greece and Cyprus.

In September, G Medical said the US Food and Drug Administration approved the Prizma mobile telephone jackets, incorporating sensors to measure vital signs and biometric parameters (BD: Sep 4, 2017).

Today, the company said that Medtl would distribute the Prizma case and planned products, exclusively in Greece and Cyprus, and would provide \$US500,000 for a 24 hours a day, seven days a week medical call centre service.

G Medical said Medtl agreed to buy a minimum number of cases in the first year worth \$US10.5 million, with the minimum increasing at 25 percent a year, but if Medtl failed to buy the agreed minima it could change the agreement to non-exclusive or terminate it.

G Medical was up 1.5 cents or 3.5 percent to 44 cents with 1.1 million shares traded.

ITL HEALTH

ITL has requested a trading halt "pending an announcement ... of an update in relation to a material transaction".

Trading will resume on October 4, 2017 or on an earlier announcement.

ITL last traded at 39.5 cents.

ANTEO DIAGNOSTICS

The ASX says that Anteo was suspended from the start of trading today, October 2, 2017 following the failure to lodge its accounts for the year to June 30, 2017.

Anteo was the only biotechnology company in the list of 12 suspended companies.

Anteo last traded at 1.4 cents.

BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT SEP 30, 2017

Company \$Am	Oct-16	Sep-17	Oct-17
Cochlear	8,114	8,985	9,161
CSL	49,188	58,153	60,628
Resmed	11,858	13,649	13,848
BDI-20			
Admedus	81	64	66
Airxpanders	323	190	223
Bionomics	221	236	229
Clinuvel	290	347	321
Compumedics	107	69	65
Ellex	138	112	132
Impedimed	601	235	299
Medical Developments	317	296	305
Mesoblast	424	625	645
Nanosonics	1,006	777	781
Neuren	88	121	153
Opthea	110	136	144
Pharmaxis	86	86	85
Polynovo	156	122	166
Prima	79	57	59
Pro Medicus	583	517	610
Psivida	140	60	61
Reva	542	321	307
Sirtex	1,852	865	771
Viralytics	219	229	195
Second 20			
Acrux	57	43	24
Actinogen	25	27	35
Avita	64	41	42
Benitec	14	25	29
Cellmid	29	26	27
Cyclopharm	72	53	51
Dimerix	21	16	15
Factor Therapeutics	40	43	41
Genetic Signatures	38	43	40
ITL Health	20	39	38
LBT Innovations	22	43	45
Living Cell	38	71	103
Oncosil	56	45	56
Orthocell	28	22	23
Osprey	98	131	143
Prana	56	28	30
Starpharma	240	384	471
Universal Biosensors	51	67	65
Uscom	27	20	19
Volpara	37	51	60

* Biotech Daily editor, David Langsam, owns shares in Acrux, Admedus, Benitec, Mesoblast, Nanosonics, Optiscan, Volpara and non-biotechnology stocks. Through Australian Ethical Superannuation he has an indirect interest in a range of other biotechnology companies: <http://www.australianethical.com.au/who-we-invest-in>. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 5000, Carlton, Victoria, Australia, 3053
email: editor@biotechdaily.com.au; www.biotechdaily.com.au; twitter: @biotech_daily